BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Relmada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 11:56 am Sale |
2022-12-31 | 13G | Relmada Therapeutics, Inc. RLMD |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-1,647,400 (Position Closed) |
Filing |
| 2021-12-20 4:51 pm Purchase |
2021-12-09 | 13G | Relmada Therapeutics, Inc. RLMD |
BIOTECHNOLOGY VALUE FUND L P | 1,647,400 5.900% |
1,647,400 (New Position) |
Filing |